Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says
Executive Summary
The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments
You may also be interested in...
AHRQ NSAID final report
Agency for Healthcare Research & Quality publishes final report on comparative effectiveness of osteoarthritis treatments. Report makes no significant departures from draft, which found that Pfizer's COX-2 inhibitor Celebrex has a safety benefit vs. non-selective NSAIDs (1"The Pink Sheet" Feb. 28, 2006, p. 23)...
AHRQ NSAID final report
Agency for Healthcare Research & Quality publishes final report on comparative effectiveness of osteoarthritis treatments. Report makes no significant departures from draft, which found that Pfizer's COX-2 inhibitor Celebrex has a safety benefit vs. non-selective NSAIDs (1"The Pink Sheet" Feb. 28, 2006, p. 23)...
Osteoporosis Drugs Found To Be Equally Effective – AHRQ Report
An Agency for Healthcare Research & Quality draft report on osteoporosis treatments found that bisphosphonates are not demonstrably superior to less costly treatments